Felipe Couñago PhD
@fcounago
Followers
3K
Following
10K
Media
1K
Statuses
9K
Rad Onc. National Clinical Director of GenesisCare Spain. San Francisco de Asis, La Milagrosa Hospitals. National Chair of Research. MRIdian Project
Guindalera, Madrid
Joined March 2013
🕒 Timing matters in radiotherapy! Great review in WJCO: 🧠 “Radiotherapy treatment time delay evidence, part I.” 👏 Congrats to the authors for this timely and valuable work! 📖 https://t.co/WvDkV35DyY
#Oncology #Radiotherapy #TimeMatters
0
2
0
Radiotherapy treatment time delay evidence ⌛⏱️, part I: Update on cervical, anal, prostate, and head and neck cancers #radonc Jose Antonio González Ferreira, Castalia Fernandez @FuenteApolo, Daniela Gonsalves @dgpieretti, Imanol Paguey, Felipe Couñago @fcounago
0
1
4
Radiation Oncology Without Limits: RECORD25 - Felipe Couñago (@fcounago) https://t.co/M5xj56csXJ
#OncoDaily #Oncology #Cancer #Health #Medicine #RECORD25 #MedX
0
1
5
Huge 🙏 to @fcounago & @F_lopez_campos for their outstanding leadership at the @RecordatiEspana Congress! 💥A big honor to represent “the rest of the 🌍” with this incredible team: @VedangMurthy @PaulSargos @BarbaraJereczek
0
4
12
Incredible days at #RECORD Madrid! Amazing to meet RadOnc leaders like @VedangMurthy @StAr_MCM74 @PaulSargos @BarbaraJereczek Thanks to the organizers @fcounago @F_lopez_campos
0
2
6
Indeed! What an amazing event ! Very funny and great discussions! Great to share time with lots of national and international friends !
🇪🇸Still inspired after an amazing RECORD event in Madrid! ��This prostate cancer meeting was truly exceptional — full of meaningful discussions. Thanks to our Spanish colleagues 🙏 🌎Does the Spanish or the rest of the world team win the 4 battles? I don't tell you, but...
0
1
9
@fcounago @PaulSargos @F_lopez_campos @BarbaraJereczek @StAr_MCM74 @RecordatiEspana Thank you for your hospitality. I made so many friends and the format was simply Superb Felipe and Fernando. Very refreshing. Lots of time to discuss and deliberate the nuances of #ProstateCancer And many thanks to @agomeziturriaga for being such a great sport! 😀
2
2
7
✨ Two amazing days at #RECORD Onco Radio Day inMadrid! Honored to co-chair with @F_lopez_campos 4 titans: @PaulSargos , @VedangMurthy , @BarbaraJereczek & @StAr_MCM74 🌟. Thanks to all panelists, attendees, and @RecordatiEspana! Will we ever see @PaulSargos in a tie again? 😄
1
4
21
🇪🇸Still inspired after an amazing RECORD event in Madrid! ✨This prostate cancer meeting was truly exceptional — full of meaningful discussions. Thanks to our Spanish colleagues 🙏 🌎Does the Spanish or the rest of the world team win the 4 battles? I don't tell you, but...
0
3
17
Key Clinical Trials in Lung and GU Cancers at ESMO 2025 - Felipe Couñago (@fcounago) https://t.co/4wK1Lk3mOi
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025 #LungCancer #GUOnc @myESMO
0
2
6
@abraocantoMD @GuardConsortium @fcounago @F_lopez_campos Muchas gracias @abraocantoMD por contar conmigo y un placer colaborar con todos!enhorabuena😘
0
1
4
Volvemos de #ESMO25 con una participación muy destacada de los miembros de @GuardConsortium como autores de algunos de los estudios más importantes presentados este año.
1
6
9
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
tlcr.amegroups.org
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
1
9
16
🩺 Miembros de GUARD Consortium presentes estos días en #ESMO2025, el gran encuentro europeo de oncología. Un espacio clave para compartir conocimiento, generar sinergias y seguir impulsando la innovación en tumores genitourinarios. #GUARDConsortium #OncologíaGU #ESMO25
0
8
15
📌ESMO 2025 Day 3 Highlights Not to Miss @shhovsepyan @emadshash @Sidi2Zacharoula @darioT_ @fcounago @FRANCES88189587 @oncology_bg @JoachimSchuz @EORTC @myESMO @RuhlmannC @JiaJennyLiu @ArmandOrlandi @ErikaHamilton9 @matteolambe @montypal @FordePatrick @eddy_saad @tmprowell
0
11
16
Good science + good laughs = perfect combo 😄🙌 Great time at #ESMO25 with my friend @_ShankarSiva , a true 🌟 in #RadiationOncology! His talk on SBRT for oligoprogression was 🔥: shaping the future of #mRCC care! @OncoAlert @MedicalwatchHQ #SBRT #ESMO2025 #OncoFriends
0
6
20
9/ KEYNOTE-905 (EV-303) – MIBC, cisplatin-ineligible; periop pembrolizumab + enfortumab vedotin ✅ Improved EFS / OS / pCR 💡 May influence sequencing with bladder-sparing RT. #BladderCancer #Immunotherapy
0
0
0
8/ EMBARK – High-risk BCR; enzalutamide + leuprolide ± RT ✅ ~40 % ↓ risk of death vs ADT alone 💡 Supports integrating RT + androgen-targeted therapy in the BCR setting. #EMBARK #ProstateCancer #RadiationOncology
1
0
0
7/ PRESTO (AFT-19) – High-risk biochemical recurrence; ADT ± apalutamide ± abiraterone (52 wks, no RT) ✅❌ Positive for PSA-PFS, negative for MFS 💡 Demonstrates biological efficacy of short-course intensified ADT. NCCN 2026: ADT + apalutamide (Category 2B) for high-risk BCR.
1
0
0
6/ ENZARAD – Localized high-risk PCa; ADT + enzalutamide + RT ❌ No MFS benefit, ↑ toxicity → Does not support escalation (except maybe N⁺ pts). #ProstateCancer #RadiationOncology
1
0
1